Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
BWX Technologies $500M Debt Financing with U.S. Bank Trust Company, National Association
BWX Technologies issued $500 million of 6.500% Senior Notes due 2034 in a private placement. The proceeds were used to fund a tender offer and consent solicitation to purchase and amend its existing 4.125% Senior Notes due 2028 and 2029, effectively refinancing its near-term debt.
Columbus Circle Capital Corp III is a shell company that completed its IPO on July 10, 2026, raising $230 million held in a trust account. As of September 30, 2026, the company has 23,665,000 Class A and 7,666,667 Class B ordinary shares outstanding and is seeking a business combination within a 24-month period.
SmartKem, Inc. reported a net loss of $24.1 million for the nine months ended September 30, 2026, significantly impacted by a $45.6 million loss on the write-off of bad debts and $11.9 million in ELOC commitment share expenses. Despite these losses, the company improved its balance sheet through debt-to-equity conversions and preferred stock issuances, ending the period with $4.3 million in cash and total stockholders' equity of $12.8 million.
Our Bond, Inc. reported a significant increase in net loss to $16.1 million for the nine months ended September 30, 2026, compared to $7.8 million in the prior year, driven by a doubling of operating expenses. Revenue slightly declined to $6.98 million, while the company maintained a stockholders' deficit of $16.97 million.
CERo Therapeutics Holdings, Inc. is an emerging growth company focused on developing its lead product candidate, CER-1236. As of November 13, 2026, the company reported 83,309,742 shares of common stock outstanding and noted the impact of its delisting from Nasdaq as a significant risk factor.
For the nine months ended September 30, 2026, CIFC Direct Lending Evergreen Fund reported total investment income of $22.8 million and net investment income of $10.3 million. Total net assets grew to $112.1 million, supported by $11.0 million in net increase from operations and $9.0 million in capital contributions, partially offset by $9.9 million in distributions and redemptions.
OptimizeRx reported Q3 2026 revenue of $21.6 million, a 17% year-over-year decrease, while GAAP net income rose to $1.2 million. The company updated its full-year 2026 revenue guidance to $87-$93 million but maintained its adjusted EBITDA outlook. Management highlighted significant margin expansion and a reduction in debt principal to $10.4 million.
Term
Q3 2026
“Third quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continued margin expansion, disciplined execution, and the resilience of our operating model. While revenue declined year-over-year, adjusted EBITDA increased approximately 23%, with adjusted EBITDA margins expanding over 900 basis points, demonstrating the benefits of our improved product mix and cost management initiatives.”
Stephen L. Silvestro, OptimizeRx CEO
“While in-year contracted revenue continues to track below prior-year levels, resulting in a revision to our full-year 2026 revenue outlook, we remain encouraged by the growth we are seeing in contracted revenue for 2027, highlighting a start to a strong RFP season.”
Texas Capital Bancshares, Inc. furnished a formal presentation deck titled 'Annual Governance Discussion Materials 2026' as part of its stockholder engagement program. The materials cover the company's governance structure, strategic plans, and financial condition for discussion with stockholders and other constituents.
Upland Software Insider John T. Mcdonald Sells $47.4K of Stock
John T. Mcdonald sold 15,000 shares of Upland Software, Inc. at $3.16 a share, worth $47.4K in total on Nov 11, 2026. Shares held after the trade: 249,088 (-5.7%).
The NYSE has commenced proceedings to delist PSQ Holdings' Class A common stock and public warrants after the company failed to maintain a minimum average global market capitalization of $15 million. Trading on the NYSE was suspended immediately on November 9, 2026, and the securities transitioned to the Pink Limited Market. The company does not intend to appeal the delisting determination and is seeking a listing on the OTCQB Venture Market.
BorgWarner Inc. filed an amendment to a previous 8-K to disclose the committee assignments for Rajesh Kalathur, who was appointed to the Board of Directors on July 30, 2026. The Board has now appointed Mr. Kalathur to serve as a member of the Audit Committee, effective November 11, 2026.
For the nine months ended September 30, 2026, FB Bancorp reported net income of $515 thousand, a significant decrease from $2.66 million in the prior year period, primarily due to a $1.14 million loss from discontinued operations and increased non-interest expenses. Total assets decreased to $1.21 billion from $1.26 billion at year-end 2025, while stockholders' equity was impacted by $32.3 million in common stock repurchases.
Yorkville International Capital Corp. is a special purpose acquisition company (SPAC) that completed its IPO on June 17, 2026, raising $230 million held in a trust account. As of September 30, 2026, the company is in its search phase for an initial business combination and reported 23,000,000 Class A and 15,333,333 Class B ordinary shares outstanding.
TRG Latin America Acquisitions Corp. is a special purpose acquisition company (SPAC) that completed its IPO on February 27, 2026, raising proceeds for a trust account totaling $210,677,645 as of September 30, 2026. The company is currently in its combination period with a deadline of February 27, 2028, to consummate an initial business combination.
John Christopher Shelton was elected to the Board of Directors of IPALCO Enterprises, Inc. to fill a vacancy. Mr. Shelton, who currently serves as Senior Vice President and Chief Product Officer of The AES Corporation, was nominated by AES U.S. Investments, Inc. pursuant to a shareholders' agreement. He will not receive separate compensation for his service on the IPALCO Board.
American Tower $1.5B Debt Financing with U.S. Bank Trust Company, National Association
American Tower Corporation completed a registered public offering of $1.5 billion in aggregate principal amount of senior unsecured notes across three tranches maturing in 2031, 2033, and 2036. The net proceeds of approximately $1,474.9 million are intended to repay existing indebtedness under the company's $6.0 billion multicurrency revolving credit facility and for general corporate purposes.
Pony Group Inc. reported a net loss of $147,554 for the nine months ended September 30, 2026, compared to a loss of $115,100 in the prior year period. Total revenue decreased slightly to $97,880 from $104,137, while the company continues to operate with a significant stockholders' deficit of $1,100,109.
Owlet, Inc. reported 29,889,307 shares of Class A Common Stock outstanding as of November 9, 2026. The filing highlights significant risks including a history of losses, reliance on single manufacturers for key products like Dream Sock and Owlet Cam, and a recent camera cable guard safety update and stop sale initiated in November 2026.
Bluejay Diagnostics provided a corporate update for Q3 2026, highlighting the completion of enrollment for its SYMON-II clinical study and the establishment of an alternative manufacturing site ahead of schedule. The company reported a cash balance of $7.38 million and targets an FDA 510(k) submission for its Symphony IL-6 platform in the first half of 2027.
Curis reported financial results for the third quarter of 2026 and provided an operational update on its TakeAim CLL and TakeAim Lymphoma clinical trials. The company highlighted progress in combining emavusertib with BTK inhibitors for the treatment of CLL and PCNSL, with initial data from the TakeAim CLL study expected in December 2026.
Term
Q3 2026
“The excitement among clinicians and patients reflects the clear unmet need in both CLL and PCNSL, where emavusertib has the potential to change the treatment landscape when combined with approved BTK inhibitors.”
TherapeuticsMD reported third quarter 2026 financial results, highlighting license revenue of $1.3 million, a 60.6% increase year-over-year. The company achieved a $0.5 million net income from continuing operations and ended the period with $10.4 million in cash. Management noted the achievement of a sales-based milestone for IMVEXXY and continues to evaluate strategic alternatives including potential mergers or asset sales.
Skyworks Solutions announced committee assignments for newly appointed directors Richard L. Clemmer and Christopher R. Koopmans. Mr. Clemmer will join the Compensation and Talent Committee, while Mr. Koopmans will join the Nominating and Corporate Governance Committee, effective November 11, 2026.
Espey Mfg. & Electronics Corp. reported net sales of $10.6 million for the quarter ended September 30, 2026, a 16.7% increase over the prior year. Despite higher sales, net income remained relatively flat at $2.19 million due to increased cost of sales and lower interest income.
BullFrog AI Holdings, Inc. reported a net loss of $4,976,572 for the nine months ended September 30, 2026, compared to a loss of $5,017,894 in the prior year period. While collaboration revenue increased to $278,963, the company continues to incur significant operating expenses primarily driven by general and administrative costs and research and development.
OptimumBank Holdings, Inc. reported a significant increase in net income to $18.5 million for the nine months ended September 30, 2026, compared to $11.8 million in the prior year. Total assets grew to $1.58 billion, driven by a substantial increase in the loan portfolio and the issuance of $34.4 million in subordinated debt.
Skye Bioscience reported a significant decrease in cash and short-term investments from $25.7 million at year-end 2025 to $4.8 million as of September 30, 2026. The company experienced a net loss of $23.2 million for the first nine months of 2026, driven primarily by $13.2 million in research and development expenses. A 1-for-8 reverse stock split was effected on August 24, 2026.
National Presto Industries reported a significant increase in net earnings for the nine months ended October 4, 2026, reaching $42.5 million compared to $18.1 million in the prior year period. This growth was driven by a 20.6% increase in net sales to $409.6 million and improved gross profit margins, alongside a $1.7 million gain from the sale of property, plant, and equipment.
LCI Industries entered into a transaction bonus agreement with its CFO, Lillian D. Etzkorn, in recognition of her efforts regarding the pending merger with Patrick Industries. Ms. Etzkorn is eligible for a cash bonus of $486,675, with 40% vesting upon the merger closing (or termination) and 60% vesting six months after the closing date, subject to continued employment.
Creative Medical Technology Holdings Nasdaq/NYSE Compliance Notice
Creative Medical Technology Holdings received a deficiency notice from Nasdaq on November 10, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has until May 10, 2027, to regain compliance by having its stock close at or above $1.00 for at least ten consecutive business days. The notice has no immediate impact on the listing of the company's common stock (CELZ).
Orrstown Financial Services executed a strategic repositioning of its available-for-sale (AFS) securities portfolio, selling $185.6 million in securities with a 3.13% yield to reinvest in higher-yielding securities at approximately 5.20%. The transaction will result in a $13.8 million pre-tax loss in Q4 2026 but is expected to be accretive to net interest margin and earnings in future periods.